RxDoctor Payments Data

Margi Patel

Optometrist · Mount Dora, FLNPI 1538416177

Payments from drug & device makers

$2,364in general payments, 2019–2025

Across 49 payments — averaging $48.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$710
  • AbbVie$530
  • Alcon$271
  • Rxsight Inc$215
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$170
  • Bausch & Lomb Americas Inc.$136
  • plus $332 from 7 others

What the payments were for

  • Travel & lodging$37716%
  • Food & beverage$1,98784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,364 in reported general payments places this provider in the 75th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$45,932
Medicare patients
236
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine79$121,742
LumiganBimatoprost67$38,415
XiidraLifitegrast21$32,012
Cyclosporine18$12,638
RocklatanNetarsudil Mesylat/Latanoprost28$11,237
EysuvisLoteprednol Etabonate22$10,729
CombiganBrimonidine Tartrate/Timolol23$8,087
Latanoprost432$4,786
Prednisolone Acetate116$3,364
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat162$2,236
Loteprednol Etabonate14$2,040
Brimonidine Tartrate84$2,002
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$1,535
Timolol Maleate67$818
Ketorolac Tromethamine28$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$530$168,244169 claims
Bausch & Lomb Americas Inc.Xiidra$136$32,01221 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$170$2,04014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Mount Dora

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →